Key result
The fifth biennial PANDA symposium convened 135 stakeholders to review the current state of research on anesthetic neurotoxicity in children and discuss future directions.
The fifth PANDA symposium gathered 135 stakeholders to discuss the current state and future directions of research on anesthetic neurotoxicity in children.
Symposium underscores gaps in translating neurotoxicity data to practice; leaves open optimal pediatric anesthesia strategies pending prospective trials.
On April 16 and 17, 2016, the Pediatric Anesthesia and Neurodevelopment Assessment (PANDA) study held its fifth biennial symposium at the Morgan Stanley Children’s Hospital of New York. The PANDA symposium has served as a key forum for clinicians, researchers, and other major stakeholders to gather and review the current state of preclinical and clinical research related to anesthetic neurotoxicity in children. Goals of the meeting included assessing how current knowledge has translated and impacted clinical care of patients who may be at risk, and future directions for research and policy. The program participants represented a diverse group with a shared concern of potential anesthetic neurotoxicity in children. It included clinicians, preclinical and clinical researchers as well as representatives from government organizations (FDA [Food and Drug Administration] and National Institutes of Health). A total of 135 attended the symposium.
No takes yet. Share an insight, caveat, or question.
Miller et al. (2016) studied Anesthetic neurotoxicity in children (n=135). The fifth biennial PANDA symposium convened 135 stakeholders to review the current state of research on anesthetic neurotoxicity in children and discuss future directions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: